Reduced GATA3 expression during breast cancer progression: A potential anchor for pulmonary metastatic deposition
Authors:
- 13 January 2025
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 266, 155821
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Cancer metastasis: Molecular mechanisms and clinical perspectivesPharmacology & Therapeutics, 2023
- Characterizing Clinicopathologic Features of Estrogen Receptor-Positive/Progesterone Receptor-Negative Breast CancersClinical Breast Cancer, 2022
- Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review StudyClinical Breast Cancer, 2022
- Characterization of estrogen receptor-low-positive breast cancerBreast Cancer Research and Treatment, 2021
- Prognostic outcomes in advanced breast cancer: the metastasis-free interval is importantHuman Pathology, 2017
- GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomasHuman Pathology, 2013
- Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organsAnnals of Diagnostic Pathology, 2011
- GATA-3 Links Tumor Differentiation and Dissemination in a Luminal Breast Cancer ModelCancer Cell, 2008
- Genes that mediate breast cancer metastasis to lungNature, 2005
- Survival of patients with metastatic breast carcinomaCancer, 2003